Erlotinib
Small molecule targets EGFR, ERBB2, JAK2, SYK via inhibition
Regulatory milestones approvals, filings & regulatory actions · 10 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (8) | US (FDA) | TARCEVA | — | 2005-11-02 – 2016-10-18 | fda.gov ↗ |
| Approved | EU (EMA) | Tarceva | — | 2005-09-19 | europa.eu ↗ |
| Approved | US (FDA) | TARCEVA | — | 2004-11-18 | fda.gov ↗ |
Trials 609 · started per year
Also used as a comparator or background therapy in 144 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 124 trials | ||||||
| Phase 1 | NCT07271446 Background | Sep 2018 → Aug 2019 | non-small cell lung carcinoma | Precision Biotech Taiwan Corp. | Completed | No outcome recorded |
| Phase 1 | NCT03050411 Background | May 2016 → Jun 2019 | non-small cell lung carcinoma | Peking University Third Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT03403049 Background | Apr 2016 → Jul 2019 | malignant pancreatic neoplasm | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT02321293 Background | Aug 2015 → Aug 2016 | lung cancer | Lady Davis Institute | Unknown | No outcome recorded |
| Phase 1 | NCT01851096 Background | Mar 2013 → Oct 2015 | cancer | Esanex Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01602289 Background | Jun 2012 → Aug 2014 | lymphoma, non-small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01594398 Background | May 2012 → Apr 2014 | estrogen-receptor positive breast cancer, non-small cell lung carcinoma | Syndax Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01472016 Background | Oct 2011 → Apr 2017 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT01199068 Background | Jun 2010 → Dec 2011 | non-small cell lung carcinoma | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT01009073 Background | Oct 2009 → Jun 2013 | cancer | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT00975182 Background | Sep 2009 → Sep 2014 | non-small cell lung carcinoma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00954525 Background | Jul 2009 → Dec 2011 | malignant pancreatic neoplasm | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 1 | NCT00848718 Background | Mar 2009 → May 2011 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00739453 Background | Oct 2008 → Mar 2012 | cancer | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT00725634 Background | Sep 2008 → Dec 2010 | plasma cell myeloma | AVEO Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00612703 Background | Feb 2008 → Sep 2010 | cancer | ArQule, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00707252 Background | Jan 2008 → Nov 2012 | non-small cell lung carcinoma | Louisiana State University Health Sciences Center Shreveport | Terminated | No outcome recorded |
| Phase 1 | NCT00591383 Background | Jan 2008 → Jun 2013 | cancer | Alaunos Therapeutics | Unknown | No outcome recorded |
| Phase 1 | NCT00565487 Background | Dec 2007 → Aug 2014 | malignant pancreatic neoplasm | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00881166 Background | Nov 2007 → Dec 2009 | cancer | Astex Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00569114 Background | Oct 2007 → Apr 2009 | non-small cell lung carcinoma | Tragara Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00705874 Background | May 2006 → Aug 2011 | cancer | Progen Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00456833 Comparator | Jun 2005 → Mar 2011 | non-small cell lung carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00072072 Background | Aug 2003 → Jan 2006 | lung cancer | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1/214 trials | ||||||
| Phase 1/2 | NCT07418177 Background | Feb 2026 → Jun 2028 expected | age-related macular degeneration | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT04165031 Background | Nov 2019 → Oct 2020 | colorectal cancer, non-small cell lung carcinoma | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 1/2 | NCT03799094 Background | Dec 2018 → Dec 2020 | non-small cell lung carcinoma | Clifford Hospital, Guangzhou, China | Unknown | No outcome recorded |
| Phase 1/2 | NCT02906163 Background | Oct 2016 → Dec 2019 | lung cancer | SciClone Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1/2 | NCT02737228 Background | Mar 2016 → Aug 2019 | malignant pancreatic neoplasm | CrystalGenomics, Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT01801111 Background | Jun 2013 → Oct 2014 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT01211483 Background | Sep 2010 → Oct 2013 | non-small cell lung carcinoma | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1/2 | NCT01178411 Background | Aug 2010 → Jan 2019 | cancer | ArQule, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01068587 Comparator | Jan 2010 → Mar 2014 | lung cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 1/2 | NCT00954512 Background | Sep 2009 → Jun 2011 | neoplasm | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1/2 | NCT00716456 Background | Jul 2008 → May 2011 | lung adenocarcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00617708 Background | Mar 2008 → Sep 2012 | pancreas disorder | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00602030 Background | Jan 2008 → Feb 2010 | non-small cell lung carcinoma | Syndax Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT01600807 Background | — | pancreatic ductal adenocarcinoma | Dana-Farber Cancer Institute | Withdrawn | No outcome recorded |
| Phase 262 trials | ||||||
| Phase 2 | NCT05442060 Background | Jul 2022 → Dec 2025 overdue | non-small cell lung carcinoma | OBI Pharma, Inc | Recruiting | No outcome recorded |
| Phase 2 | NCT04455594 Comparator | Oct 2020 → Jan 2023 | non-small cell lung carcinoma | The First Affiliated Hospital of Guangzhou Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT05081674 Comparator | Jan 2020 → Jun 2023 | lung neoplasm | Hospital Israelita Albert Einstein | Completed | No outcome recorded |
| Phase 2 | NCT03389256 Background | Dec 2018 → Dec 2020 | non-small cell lung carcinoma | Sichuan Cancer Hospital and Research Institute | Unknown | No outcome recorded |
| Phase 2 | NCT03461185 Background | May 2018 → Aug 2019 | non-small cell lung carcinoma | Xinqiao Hospital of Chongqing | Unknown | No outcome recorded |
| Phase 2 | NCT03119519 Background | Dec 2017 → Sep 2020 | non-small cell lung carcinoma | Southern Medical University, China | Unknown | No outcome recorded |
| Phase 2 | NCT02655536 Comparator | Aug 2017 → Jun 2019 | brain neoplasm, non-small cell lung carcinoma | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03137771 Background | Apr 2017 → Dec 2023 overdue | non-small cell lung carcinoma | NRG Oncology | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03123484 Background | Apr 2017 → Apr 2019 | non-small cell lung carcinoma | China Medical University, China | Unknown | No outcome recorded |
| Phase 2 | NCT03595644 Background | Feb 2017 → Jun 2019 | non-small cell lung carcinoma | Tongji Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02704767 Background | Jun 2016 → Jun 2019 | lung cancer | First Affiliated Hospital of Kunming Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT02788058 Background | May 2016 → May 2021 | lung adenocarcinoma | First People's Hospital of Hangzhou | Unknown | No outcome recorded |
| Phase 2 | NCT02787447 Background | May 2016 → Dec 2017 | lung adenocarcinoma | First People's Hospital of Hangzhou | Unknown | No outcome recorded |
| Phase 2 | NCT02355431 Background | Dec 2014 → Sep 2015 | hematopoietic and lymphoid cell neoplasm, non-small cell lung carcinoma | Incyte Corporation | Withdrawn | No outcome recorded |
| Phase 2 | NCT02318368 Background | Nov 2014 → Jan 2017 | non-small cell lung carcinoma | AVEO Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02117024 Comparator | Jul 2014 → Dec 2017 | non-small cell lung carcinoma | Heat Biologics | Terminated | No outcome recorded |
| Phase 2 | NCT02004262 Comparator | Feb 2014 → Jan 2016 | — | Aduro Biotech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02045446 Background | Feb 2014 → Feb 2022 | non-small cell lung carcinoma | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01703910 Comparator | Nov 2012 | colon adenocarcinoma, metastatic neoplasm, rectum adenocarcinoma | Spanish National Cancer Research Centre | Completed | No outcome recorded |
| Phase 2 | NCT01556191 Background | May 2012 → May 2018 | — | French Cooperative Thoracic Intergroup | Completed | No outcome recorded |
| Phase 2 | NCT01580735 Background | May 2012 → Apr 2015 | non-small cell lung carcinoma | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02036359 Comparator | May 2012 → Jun 2015 | non-small cell lung carcinoma | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01505530 Background | Dec 2011 → Oct 2014 | malignant pancreatic neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT01454180 Comparator | Oct 2011 | exocrine pancreatic carcinoma | Spanish National Cancer Research Centre | Completed | No outcome recorded |
| Phase 2 | NCT01186861 Background | Mar 2011 → Jul 2013 | non-small cell lung carcinoma | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 2 | NCT01306045 Comparator | Feb 2011 → Feb 2014 | non-small cell lung carcinoma, small cell lung carcinoma, thymic carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01303029 Comparator | Feb 2011 → Jun 2015 | malignant pancreatic neoplasm | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Completed | No outcome recorded |
| Phase 2 | NCT01376310 Background | Nov 2010 → Jan 2018 | cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT01229150 Comparator | Oct 2010 → Sep 2013 | non-small cell lung carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01210911 Background | Aug 2010 → Feb 2014 | malignant pancreatic neoplasm | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| Phase 2 | NCT01131429 Comparator | Jun 2010 → Jun 2013 | non-small cell lung carcinoma | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01116219 Comparator | Jun 2010 → Jul 2014 | lung cancer | Swiss Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT01187901 Comparator | Apr 2010 → Jun 2014 | classic or attenuated familial adenomatous polyposis | University of Utah | Completed | No outcome recorded |
| Phase 2 | NCT01101334 Background | Mar 2010 → Apr 2013 | non-small cell lung carcinoma | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT01344824 Background | Mar 2010 → May 2016 | lung cancer | UNC Lineberger Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01104155 Comparator | Feb 2010 → Apr 2011 | non-small cell lung carcinoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00800202 Background | Apr 2009 → Oct 2012 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00743938 Comparator | Mar 2009 → Aug 2010 | non-small cell lung carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT00835471 Comparator | Mar 2009 → Jun 2014 | non-small cell lung carcinoma | Dutch Society of Physicians for Pulmonology and Tuberculosis | Completed | No outcome recorded |
| Phase 2 | NCT00550836 Background | Mar 2009 → Nov 2010 | malignant pancreatic neoplasm | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 2 | NCT00473083 Background | Jan 2009 → Dec 2012 | exanthem | British Columbia Cancer Agency | Completed | No outcome recorded |
| Phase 2 | NCT00661193 Comparator | Dec 2008 → Dec 2015 | lung cancer | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 2 | NCT00760929 Background | Nov 2008 → Jun 2010 | non-small cell lung carcinoma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 2 | NCT00769067 Comparator | Nov 2008 → Oct 2010 | non-small cell lung carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00777309 Background | Sep 2008 → May 2011 | non-small cell lung carcinoma | ArQule, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00750698 Background | Aug 2008 → May 2010 | non-small cell lung carcinoma | Syndax Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT00709826 Background | Aug 2008 → Jun 2010 | malignant pancreatic neoplasm | Tragara Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00732810 Comparator | Jul 2008 → Jun 2011 | breast neoplasm, non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00652340 Background | Apr 2008 → Jun 2010 | non-small cell lung carcinoma | Tragara Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00654420 Comparator | Mar 2008 → Nov 2009 | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00600015 Background | Feb 2008 → Feb 2009 | non-small cell lung carcinoma | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00642473 Background | Feb 2008 → Mar 2009 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00606502 Comparator | Jan 2008 → Jun 2010 | non-small cell lung carcinoma | Spectrum Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 2 | NCT00531934 Background | Oct 2007 → Aug 2010 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00592007 Background | Sep 2007 → Jan 2012 | non-small cell lung carcinoma | Lyudmila Bazhenova, M.D. | Terminated | No outcome recorded |
| Phase 2 | NCT01243047 Comparator | Sep 2007 → Oct 2012 | colorectal cancer | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 2 | NCT00536770 Comparator | Sep 2007 → ? | malignant pancreatic neoplasm | Novacea | Suspended | No outcome recorded |
| Phase 2 | NCT00392665 Comparator | Oct 2006 → Aug 2012 | head and neck squamous cell carcinoma | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT00570258 Comparator | Sep 2006 → Dec 2010 | breast cancer | University of Arkansas | Terminated | No outcome recorded |
| Phase 2 | NCT00265317 Comparator | Jun 2006 → Jan 2010 | non-small cell lung carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00462995 Comparator | May 2006 → Jan 2012 | non-small cell lung carcinoma | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2 | NCT00063258 Comparator | Jun 2003 → Apr 2008 | lung cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT03653546 Comparator | Oct 2018 → Jul 2022 | metastatic malignant neoplasm in the brain, non-small cell lung carcinoma | Alpha Biopharma (Jiangsu) Co., Ltd. | Completed | No outcome recorded |
| Phase 2/3 | NCT02186301 Comparator | Nov 2014 → Jun 2017 | non-small cell lung carcinoma | Clovis Oncology, Inc. | Terminated | No outcome recorded |
| Phase 334 trials | ||||||
| Phase 3 | NCT03529084 Comparator | Jul 2018 → Aug 2020 | non-small cell lung carcinoma | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 3 | NCT02775006 Comparator | Oct 2016 → Apr 2019 | non-small cell lung carcinoma | The Netherlands Cancer Institute | Terminated | No outcome recorded |
| Phase 3 | NCT02759614 Background | Apr 2016 → Jun 2018 | non-small cell lung carcinoma | Guangdong Association of Clinical Trials | Completed | No outcome recorded |
| Phase 3 | NCT02588261 Comparator | Feb 2016 → Dec 2017 | non-small cell lung carcinoma | Astellas Pharma Global Development, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT02893332 Background | Jan 2016 → Aug 2020 | lung cancer susceptibility 4 | Sichuan Provincial People's Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT02488330 Background | Aug 2015 → Jun 2018 | neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02882984 Background | Mar 2015 → Mar 2020 | — | Sichuan Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02352948 Comparator | Jan 2015 → Feb 2018 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02296125 Comparator | Dec 2014 → Jun 2017 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02152631 Comparator | Oct 2014 → Sep 2017 overdue | non-small cell lung carcinoma | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02134015 Background | Mar 2014 → Nov 2016 | non-small cell lung carcinoma | Daiichi Sankyo | Terminated | No outcome recorded |
| Phase 3 | NCT02031744 Background | Jan 2014 → Jan 2016 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02001896 Comparator | Dec 2013 → Jun 2015 | non-small cell lung carcinoma | Xinjiang Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT01887886 Background | Dec 2013 → Feb 2015 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02889692 Background | Mar 2013 → Dec 2016 | cancer | Shanghai University of Traditional Chinese Medicine | Completed | No outcome recorded |
| Phase 3 | NCT01523587 Comparator | Mar 2012 → Oct 2013 | non-small cell lung carcinoma | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT01456325 Background | Jan 2012 → Jan 2016 | non-small cell lung carcinoma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01487174 Comparator | Dec 2011 → Jul 2013 | non-small cell lung carcinoma | Kadmon Corporation, LLC | Terminated | No outcome recorded |
| Phase 3 | NCT01377376 Background | Jul 2011 → Nov 2015 | non-small cell lung carcinoma | Kyowa Kirin, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT01351415 Background | Jun 2011 → Jun 2016 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01360554 Comparator | Jun 2011 → Sep 2013 | non-small cell lung carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01244191 Background | Jan 2011 → Dec 2012 | non-small cell lung carcinoma | Daiichi Sankyo | Terminated | No outcome recorded |
| Phase 3 | NCT01229813 Comparator | Oct 2010 → Dec 2013 | colorectal cancer | Lund University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01158170 Background | Jun 2010 → May 2013 | non-small cell lung carcinoma | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT00955695 Background | May 2009 → ? | lung cancer | National Cancer Center, Korea | Unknown | No outcome recorded |
| Phase 3 | NCT00718315 Background | Apr 2009 → Jun 2012 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01149122 Comparator | Jan 2009 → Jan 2012 | biliary tract cancer | Samsung Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00673049 Comparator | May 2008 → Mar 2011 | adenosquamous carcinoma, large cell carcinoma, non-small cell lung carcinoma | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00457392 Comparator | Jul 2007 → Jul 2010 | non-small cell lung carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00349219 Comparator | Dec 2006 → Dec 2011 | non-small cell lung carcinoma | National Cancer Institute, Naples | Completed | No outcome recorded |
| Phase 3 | NCT00364351 Comparator | Aug 2006 → Sep 2008 | non-small cell lung carcinoma | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00440167 Comparator | Jun 2006 → Dec 2011 | malignant pancreatic neoplasm | PD Dr. med. Volker Heinemann | Unknown | No outcome recorded |
| Phase 3 | NCT00130728 Comparator | Jun 2005 → Jul 2008 | non-small cell lung carcinoma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00026338 Comparator | Oct 2001 → Sep 2004 | malignant pancreatic neoplasm | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT04401059 Comparator | Nov 2020 → Sep 2025 | adenocarcinoma, non-small cell lung carcinoma | Tian Xie | Unknown | No outcome recorded |
| Phase 4 | NCT04356118 Background | Jun 2020 → Jun 2023 | malignant leptomeningeal tumor | Hui Bu | Unknown | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT04007835 Background | Jul 2019 → Jul 2021 | non-small cell lung carcinoma | Guangdong Association of Clinical Trials | Unknown | No outcome recorded |
| — | NCT03071705 Background | Mar 2016 → Apr 2017 | lung adenocarcinoma | National Cancer Institute of Mexico | Unknown | No outcome recorded |
| — | NCT02701231 Background | Nov 2015 → Dec 2020 | lung cancer | Chinese PLA General Hospital | Unknown | No outcome recorded |
| — | NCT02450591 Background | May 2015 → Dec 2017 | lung adenocarcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| — | NCT01776684 Background | Jun 2012 → May 2014 | lung cancer | Samsung Medical Center | Unknown | No outcome recorded |
| — | NCT00903292 Comparator | Mar 2009 → Apr 2010 | non-small cell lung carcinoma | National Cheng-Kung University Hospital | Unknown | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-05-09 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Launch of a Generic Version of Tarceva® (erlotinib) Tablets in the United States tevapharm.com ↗ |
| 2016-06-08 | Roche Global Development | Roche receives EU approval of Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer roche.com ↗ |
| 2016-04-29 | Roche Global Development | CHMP recommends EU approval for Roche's Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer roche.com ↗ |
Evidence & citations 25 cited values
Every value below carries the sentence it was read from. 758 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Erlotinib | “Tivantinib 360 mg twice daily in combination with other anti-cancer therapy (eg, erlotinib,sorafenib, pemetrexed, docataxel, gemcitabine, irinotecan, and/or cetuximab) at the...” NCT01178411 ↗696“Standard of care, gemcitabine-based regimen (single-agent gemcitabine or gemcitabine plus erlotinib) or FOLFIRINOX (combination chemotherapy regimen including 5-fluorouracil,...” NCT01505530 ↗ “Carboplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, vinorelbine, pemetrexed, or erlotinib administered on Day 1 of every 21-day cycle except gemcitabine, which was...” NCT00312728 ↗ “GEMOX-Erlotinib consists of erlotinib 100 mg orally daily starting day 1, Gemcitabine 1000 mg/m2 in 10 mg/m2/min (100 minutes) infusion on day 1 followed on day 2 by...” NCT00636883 ↗ “Patients were randomly allocated to receive EGFR-TKIs (erlotinib hydrochloride, afatinib dimaleate, or gefitinib at standard dosage) plus metformin hydrochloride (500 mg twice...” PMID 31486833 ↗ Nov 2019 “To assess the clinical efficacy, biologic effects and safety of the EGFR inhibitor erlotinib in the treatment of patients with 'triple receptor-negative' metastatic carcinoma...” NCT00739063 ↗ “Patients with advanced solid malignancies were administered oral tivantinib at escalating doses of 120, 240, 360, and 480 mg twice daily (BID) plus 150 mg erlotinib once daily (QD).” PMID 22605616 ↗ May 2012 “Investigator's choice of one of the following commercially available products: gemcitabine; capecitabine; fluorouracil with or without leucovorin; irinotecan; or erlotinib.” NCT02004262 ↗ “Erlotinib is administered 150 mg once per day , or Icotinib is administered 125 mg three times per day, until disease progression or untolerated toxicity.” NCT04007835 ↗ “COX-2 inhibitor Celecoxib and EGFR tyrosine kinase inhibitor Erlotinib alone or in combination on molecular markers of apoptosis and angiogenesis.” NCT02748707 ↗ “A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva® (Erlotinib) in Patients With Stage IIIB/IV Non-small Cell Lung Cancer” NCT00294736 ↗ “Phase I Study of Erlotinib (Tarceva) in Combination With AT-101 in Patients With Advanced Non Small Cell Lung Cancer (NSCLC)” NCT00934076 ↗ “Gefitinib(Iressa,YiRuiKe), Erlotinib(Tarceva), Icotinib(Kaimeina), Osimertinib(Tagrisso), Almonertinib, Furmonertinib, etc.” NCT04401059 ↗ “Standard EGFR-TKI(Gefitinib, erlotinib or icotinib) Gefitinib: 250mg po Qd Erlotinib: 150mg po Qd Icotinib: 125mg po tid” NCT03595644 ↗ “Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) alone, according to gene test.” NCT03119519 ↗ “FDA approved drugs for the study population: Bevacizumab, Docetaxel, Erlotinib, Gemcitabine, Pemetrexed” NCT02045446 ↗ “Erlotinib (tarceva) is oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).” NCT03086538 ↗ “apatinib 500mg qd po plus Erlotinib 150mg qd po / apatinib 500mg qd po plus Icotinib 125mg tid po” NCT03634059 ↗ “Imatinib tablets, 125 mg tid po; gefitinib tablets, 250 mg qd po; erlotinib tablets, 150 mg qd po” NCT03389256 ↗ “if EGFR mutation is positive, (gefitinib, ecotinib, erlotinib）or ALK/ROS-1 positive（Crizotinib）” NCT04193007 ↗ “Erlotinib 150mg by mouth daily during the entire course of radiation (approximately 7 weeks)” NCT00392704 ↗ “With sensitive result the first-line therapy will be Erlotinib/Gefitinib/Crizotinib.” NCT02701231 ↗ “Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally” PMID 27843623 ↗ Jul 2016 “Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid” NCT02788058 ↗ “Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid” NCT02787447 ↗ “Beginning on day 2 of treatment, receive oral erlotinib 150mg per day.” NCT02353741 ↗ “Subjects will also receive 150 mg erlotinib daily (in the afternoon).” NCT01851096 ↗ “TS (pos), EGFR Ampl or K-Ras mut (neg): Gemcitabine plus Erlotinib” NCT01394120 ↗ “All patients will also receive Erlotinib 150mg po/day from Day 1.” NCT00707252 ↗ “EGFR-TKIs include but are not limited erlotinib, gefitinib” NCT03461185 ↗ “Erlotinib in Treating Patients With Advanced Kidney Cancer” NCT00045487 ↗ “Gefitinib 250mg or Erlotinib 150mg medication, Once-Daily.” NCT03382795 ↗ “Mutated EGFR : Erlotinib 150mg/day (1 year)” NCT00775385 ↗ “Erlotinib 150 mg once a day for 4 weeks.” NCT04644432 ↗ “Erlotinib, Oxaliplatin, Capecitabine” NCT01243047 ↗ “Eribulin, Erlotinib, Estramustine” NCT02788201 ↗ “Drug: erlotinib tablets 150mg QD” NCT00569114 ↗ “Decitabine Erlotinib Etoposide” NCT02551718 ↗ “afatinib, gefitinib, erlotinib” NCT02906163 ↗ “OSI-774: erlotinib, TarcevaTM” NCT00590902 ↗ “EGFR Mutation: Erlotinib” NCT04356118 ↗ “Tarceva(TM) (erlotinib)” NCT00602667 ↗ “Sorafenib + Erlotinib” NCT00837876 ↗ “Drug: Erlotinib” NCT00611468 ↗ “Erlotinib” NCT00903734 ↗ “erlotinib” NCT00087412 ↗ “Erlotinib” NCT01703910 ↗ “Erlotinib” NCT02142036 ↗ |
| Known as | CP-358 | ChEMBL registry synonym — accepted as the source's own label CHEMBL553 ↗ |
| Known as | CP-358,774 | “Erlotinib, CP-358,774, erlotinib hydrochloride” NCT01471964 ↗ |
| Known as | CP-358,774-01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL553 ↗ |
| Known as | ERL | “Patients received three cycles of GEM (1000 mg/m2/week) plus daily erlotinib (ERL) (100 mg/day).” PMID 30225601 ↗ Sep 2018 |
| Known as | Erlotinib (OSI-774) | “Erlotinib (OSI-774)” NCT00983307 ↗ |
| Known as | erlotinib (Tarceva) | “erlotinib (Tarceva)” NCT01116219 ↗3“Erlotinib: Tarceva®” NCT00585377 ↗ “Erlotinib - Tarceva” NCT00709826 ↗ “erlotinib (Tarceva)” NCT02321293 ↗ |
| Known as | Erlotinib :- Tarceva (OSI-774) | “Erlotinib :- Tarceva™ (OSI-774)” NCT00996515 ↗1“erlotinib - Tarceva - OSI-774” NCT00672243 ↗ |
| Known as | Erlotinib chlorhydrate | “There are three cohorts of patients in whom the dose of Erlotinib chlorhydrate(100 and 150 mg) and Cisplatin (30 and 40 mg / m2) will be increase, and the doses of Radiation...” NCT00442455 ↗ |
| Known as | Erlotinib HCl | “Tarceva (Trademark) (erlotinib HCl, OSI-774)” NCT00072631 ↗14“Tarceva (Trademark) (erlotinib HCl, OSI-774)” NCT00085839 ↗ “oral erlotinib HCl 150 mg/day orally” NCT00130728 ↗ “Tarceva (erlotinib HCl, OSI-774 )” NCT00036647 ↗ “Tarceva (erlotinib HCl, OSI-774)” NCT00040183 ↗ “Drug: Erlotinib HCl 150 mg” NCT04145570 ↗ “Erlotinib HCl (OSI-774)” NCT00337883 ↗ “Erlotinib HCl (OSI-774)” NCT00109265 ↗ “Tarceva (erlotinib HCl)” NCT00091663 ↗ “Tarceva (erlotinib HCl)” NCT00095225 ↗ “Tarceva (erlotinib HCl)” NCT00047736 ↗ “Tarceva (erlotinib HCl)” NCT00081614 ↗ “Drug: erlotinib HCl” NCT00257608 ↗ “Drug: Erlotinib HCl” NCT00854308 ↗ |
| Known as | Erlotinib hydrochloride | “To characterize the safety and tolerability of the combination of erlotinib (erlotinib hydrochloride) and dovitinib (dovitinib lactate), assessing for toxicity using the Common...” NCT01515969 ↗98“Phase I Studies of TARCEVA™ (ERLOTINIB HYDROCHLORIDE, OSI-774) as Single Agent in Children With Refractory and Relapsed Malignant Brain Tumors and in Combination With...” NCT00360854 ↗ “erlotinib (erlotinib hydrochloride) doses as low as 25 mg will decrease aberrant crypt foci (ACF) phosphorylated extracellular signal-regulated kinases (pERK) levels from...” NCT00754494 ↗ “OBJECTIVES: Primary * Determine overall survival of patients with stage IIIB or IV bronchioloalveolar carcinoma (BAC) or adenocarcinoma with BAC features treated with...” NCT00436332 ↗ “Patients were randomly allocated to receive EGFR-TKIs (erlotinib hydrochloride, afatinib dimaleate, or gefitinib at standard dosage) plus metformin hydrochloride (500 mg twice...” PMID 31486833 ↗ Nov 2019 “Patients also receive oral erlotinib hydrochloride once daily beginning on day 1 of radiotherapy and continuing for up to 2 years in the absence of disease progression or...” NCT00573989 ↗ “Patients receive vinflunine IV over 20 minutes on day 1 and oral erlotinib hydrochloride once daily on days 2-21 of course 1 and on days 1-21 of all subsequent courses.” NCT00320073 ↗ “Tarceva (erlotinib hydrochloride; previously referred to as OSI-774), a quinazoline, is an orally active, potent, selective inhibitor of EGFR tyrosine kinase.” NCT00187486 ↗ “Erlotinib hydrochloride is designed to block the activity of a protein found on the surface of many tumor cells that may control tumor growth and survival.” NCT00543842 ↗ “Erlotinib hydrochloride is designed to block the activity of a protein found on the surface of many tumor cells that may control tumor growth and survival.” NCT01180959 ↗ “Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.” NCT00976677 ↗ “I. To document the toxicities, and reversibility of toxicities, of this regimen of 5-azacytidine (azacitidine) and erlotinib (erlotinib hydrochloride).” NCT00996515 ↗ “Erlotinib hydrochloride is a drug that blocks the function of the epidermal growth factor receptor (EGFR), often over expressed in kidney cancer.” NCT00353301 ↗ “Erlotinib hydrochloride is designed to help block the activity of an enzyme that is believed to play an important role in cell growth.” NCT00411632 ↗ “Tarceva (erlotinib hydrochloride), when given in addition to whole brain radiation therapy, is better to treat brain metastases” NCT00871923 ↗ “Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral erlotinib hydrochloride once daily on days 1-28.” NCT00365391 ↗ “oral erlotinib hydrochloride once daily for up to 2 years in the absence of disease progression or unacceptable toxicity” NCT00720304 ↗ “oral erlotinib hydrochloride once daily on days 1-43 in the absence of disease progression or unacceptable toxicity.” NCT00733746 ↗ “Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.” NCT01557959 ↗ “erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.” NCT01192815 ↗ “Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.” NCT00733408 ↗ “Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.” NCT00482625 ↗ “Patients receive oral erlotinib hydrochloride once daily and oral sorafenib tosylate twice daily on days 1-28.” NCT00801385 ↗ “Drug: erlotinib hydrochloride Dose Level 0 = 50 mg/day, continuous daily; 0.5= 75 mg/day, continuous daily;” NCT00425386 ↗ “Orally twice daily administration of ARQ197 and orally once daily administration of erlotinib hydrochloride” NCT01251796 ↗ “Patients receive oral erlotinib hydrochloride once daily on days 1-28. Courses repeat every 28 days.” NCT00100854 ↗ “Capecitabine and erlotinib hydrochloride are designed to interfere with the growth of cancer cells.” NCT00614653 ↗ “recommended phase II doses of erlotinib (erlotinib hydrochloride) and 13-cis-retinoic acid (CRA)” NCT01103375 ↗ “Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy” NCT02926638 ↗ “Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver” NCT02273362 ↗ “Patients also receive oral erlotinib hydrochloride once daily for up to 24 months.” NCT00554775 ↗ “Patients receive oral erlotinib hydrochloride once every 72 hours for 28 days.” NCT00227032 ↗ “Patients receive oral erlotinib hydrochloride once daily for 5-14 days.” NCT00633750 ↗ “Patients receive oral erlotinib hydrochloride once daily on days 1-28.” NCT00281866 ↗ “Patients receive oral erlotinib hydrochloride once daily on days 1-28.” NCT01068587 ↗ “Patients receive oral erlotinib hydrochloride once daily for 1 year” NCT00524121 ↗ “oral erlotinib hydrochloride once daily on days 1-28.” NCT00885066 ↗ “oral erlotinib hydrochloride once daily on days 1-21” NCT01116219 ↗ “Tarceva™ (Erlotinib Hydrochloride) Plus Sirolimus” NCT00509431 ↗ “100 mg oral erlotinib hydrochloride on days 1-28” NCT00550836 ↗ “Erlotinib, CP-358,774, erlotinib hydrochloride” NCT01471964 ↗ “treated with erlotinib hydrochloride.” NCT00416650 ↗ “erlotinib (erlotinib hydrochloride)” NCT00950365 ↗ “Tarceva (Erlotinib Hydrochloride)” NCT00418327 ↗ “Erlotinib Hydrochloride (Tarceva)” NCT00903734 ↗ “Drug: erlotinib hydrochloride” NCT00060411 ↗ “Drug: erlotinib hydrochloride” NCT00059852 ↗ “Drug: erlotinib hydrochloride” NCT00313560 ↗ “Drug: Erlotinib Hydrochloride” NCT03137771 ↗ “Drug: Erlotinib Hydrochloride” NCT02535338 ↗ “Drug: erlotinib hydrochloride” NCT00032110 ↗ “Drug: erlotinib hydrochloride” NCT00039182 ↗ “Drug: erlotinib hydrochloride” NCT00055913 ↗ “Drug: erlotinib hydrochloride” NCT00026338 ↗ “Drug: erlotinib hydrochloride” NCT00275132 ↗ “Drug: erlotinib hydrochloride” NCT00068367 ↗ “Drug: erlotinib hydrochloride” NCT00118261 ↗ “Drug: Erlotinib Hydrochloride” NCT01532089 ↗ “Drug: erlotinib hydrochloride” NCT04172779 ↗ “Drug: erlotinib hydrochloride” NCT00087412 ↗ “Drug: Erlotinib Hydrochloride” NCT02961374 ↗ “Drug: erlotinib hydrochloride” NCT00077454 ↗ “Drug: Erlotinib Hydrochloride” NCT00254384 ↗ “Drug: Erlotinib Hydrochloride” NCT00954226 ↗ “Drug: erlotinib hydrochloride” NCT00030576 ↗ “Drug: erlotinib hydrochloride” NCT00085280 ↗ “Drug: Erlotinib Hydrochloride” NCT01660971 ↗ “Drug: erlotinib hydrochloride” NCT00091026 ↗ “erlotinib hydrochloride” NCT00030446 ↗ |
| Known as | NSC-718781 | “A Phase II Trial of the Combination of OSI-774 (ERLOTINIB; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and...” NCT00436332 ↗2“A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (RHUMAB VEGF; NSC 704865) in Never-Smokers With Stage IIIB and IV Primary NSCLC Adenocarcinomas” NCT00445848 ↗ “OSI-774 (Erlotinib; NSC-718781)” NCT00661193 ↗ |
| Known as | OSI-774 | “A Phase II Trial of the Combination of OSI-774 (ERLOTINIB; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and...” NCT00436332 ↗26“Phase I Studies of TARCEVA™ (ERLOTINIB HYDROCHLORIDE, OSI-774) as Single Agent in Children With Refractory and Relapsed Malignant Brain Tumors and in Combination With...” NCT00360854 ↗ “A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (RHUMAB VEGF; NSC 704865) in Never-Smokers With Stage IIIB and IV Primary NSCLC Adenocarcinomas” NCT00445848 ↗ “OSI-774 (also known as Erlotinib or Tarceva) is a drug that helps to block the activity of an enzyme that is believed to play an important role in cell growth.” NCT00113347 ↗ “Tarceva (erlotinib hydrochloride; previously referred to as OSI-774), a quinazoline, is an orally active, potent, selective inhibitor of EGFR tyrosine kinase.” NCT00187486 ↗ “HNSCC patients treated in three escalating dose cohorts of daily continous oral erlotinib (OSI-774) and intermittent IV cisplatin given every 21 days” NCT00030576 ↗ “TarcevaTM (Erlotinib Hydrochloride, OSI-774) as Single Agent in Children With Refractory and Relapsed Malignant Brain Tumors” NCT00418327 ↗ “A Phase I Study of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib; Tarceva) in Advanced Solid Tumors” NCT00126620 ↗ “Erlotinib (Tarceva, OSI-774) can be safely used up to a dose of 150 mg two times a day for 12 months” NCT00301418 ↗ “Erlotinib (OSI-774, Tarceva) is an orally available inhibitor of human EGFR tyrosine kinase.” NCT00459901 ↗ “an EGFR tyrosine-kinase inhibitor (OSI-774, Tarceva)” NCT00243854 ↗ “Tarceva (Trademark) (erlotinib HCl, OSI-774)” NCT00085839 ↗ “Tarceva (Trademark) (erlotinib HCl, OSI-774)” NCT00072631 ↗ “Erlotinib (aka Tarceva or OSI-774)” NCT00047762 ↗ “Tarceva (erlotinib HCl, OSI-774 )” NCT00036647 ↗ “Tarceva (erlotinib HCl, OSI-774)” NCT00040183 ↗ “OSI-774 (Erlotinib; NSC-718781)” NCT00661193 ↗ “OSI-774 (Tarceva, Erlotinib)” NCT00217529 ↗ “Erlotinib HCl (OSI-774)” NCT00337883 ↗ “Erlotinib HCl (OSI-774)” NCT00109265 ↗ “Tarceva (OSI-774)” NCT00123851 ↗ |
| Known as | R-1415 | ChEMBL registry synonym — accepted as the source's own label CHEMBL553 ↗ |
| Known as | RG-1415 | ChEMBL registry synonym — accepted as the source's own label CHEMBL553 ↗ |
| Known as | Ro-508231 | ChEMBL registry synonym — accepted as the source's own label CHEMBL553 ↗ |
| Known as | Tarceva | “This randomized, Phase III, double-blind, placebo-controlled study will evaluate the safety and efficacy of MetMAb (onartuzumab) in combination with Tarceva (erlotinib)...” NCT02031744 ↗108“This single arm, open-label study will evaluate the efficacy and safety of erlotinib (Tarceva) in participants with locally advanced or metastatic non-small cell lung cancer...” NCT01260181 ↗ “Erlotinib (Tarceva®)is an oral inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase and its anti-neoplastic effect is approved especially women, patients with...” NCT01130753 ↗ “Phase I Studies of TARCEVA™ (ERLOTINIB HYDROCHLORIDE, OSI-774) as Single Agent in Children With Refractory and Relapsed Malignant Brain Tumors and in Combination With...” NCT00360854 ↗ “The purpose of this study is to determine whether Gemcitabine/Oxaliplatin (GEMOX) with or without Erlotinib (Tarceva) is effective in the treatment of unresectable, metastatic...” NCT01149122 ↗ “Participants received bevacizumab (Avastin) 5 mg/kg intravenous (iv) on day 1 of each 2 week cycle plus erlotinib (Tarceva) 150 mg orally once a day until disease progression...” NCT00605722 ↗ “A Randomized, Open-Label Phase II Clinical Trial of Combination Erlotinib (Tarceva®) and Fulvestrant (Faslodex®) Versus Erlotinib (Tarceva®) Alone in Advanced Non-Small Cell...” NCT00100854 ↗ “The purpose of this study is to learn about the effects of two new anticancer drugs, erlotinib (Tarceva) and bexarotene (Targretin), when treating patients with advanced lung cancer.” NCT00125359 ↗ “The main purpose of this research study is to see if adding fulvestrant (Faslodex) to erlotinib (Tarceva) is effective in patients with stage IIIb/IV Non-Small Cell Lung Cancer.” NCT00592007 ↗ “The Federal Drug Administration (FDA) has approved erlotinib, also known as Tarceva, for the treatment of locally advanced and metastatic non-small cell lung cancer.” NCT00597597 ↗ “OSI-774 (also known as Erlotinib or Tarceva) is a drug that helps to block the activity of an enzyme that is believed to play an important role in cell growth.” NCT00113347 ↗ “A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)” NCT00556712 ↗ “A Phase II Study of Bevacizumab (Avastin™) and Erlotinib (Tarceva™) in Combination With FOLFOX for Patients With Untreated Metastatic Colorectal Cancer” NCT00116506 ↗ “The goal of this clinical research study is to learn if Tarceva® (erlotinib hydrochloride) can help control triple receptor-negative breast cancer.” NCT00739063 ↗ “Tarceva® (erlotinib) is a drug that blocks a receptor called the Epidermal Growth Factor Receptor (EGFR) on certain cells including tumor cells.” NCT00385996 ↗ “The therapeutic trial of erlotinib (Tarceva) and bevacizumab (Avastin) for first-line treatment of Stage IIIB/IV or recurrent lung cancer” NCT00708448 ↗ “The purpose of this study is to find a safe and effective dose of the combination of cetuximab (Erbitux) and Tarceva (erlotinib).” NCT00207077 ↗ “Tarceva (erlotinib hydrochloride), when given in addition to whole brain radiation therapy, is better to treat brain metastases” NCT00871923 ↗ “Phase I Study of Erlotinib (Tarceva) in Combination With AT-101 in Patients With Advanced Non Small Cell Lung Cancer (NSCLC)” NCT00934076 ↗ “75 patients received tyrosine kinase inhibitor daily. (dose: Osimertinib 80 mg/d, or Tarceva 150 mg/d, or Iressa 0.25 g/d.)” NCT03799094 ↗ “Erlotinib (trade name: Tarceva®) (150mg oral daily) or Icotinib (trade name: Conmana®) (125mg oral three times a day).” NCT02738983 ↗ “A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.” NCT00518011 ↗ “A Phase 1 Dose Escalation Study of Daily Oral OSI-930 and Erlotinib (Tarceva) in Patients With Advanced Solid Tumors” NCT00603356 ↗ “A Phase I Study of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib; Tarceva) in Advanced Solid Tumors” NCT00126620 ↗ “Tarceva (Erlotinib) Compared With Tarceva Alone for Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)” NCT00130728 ↗ “Phase II Study of Erlotinib (Tarceva®) and Radiotherapy for Elderly Patients With Esophageal Carcinoma” NCT00524121 ↗ “Erlotinib (Tarceva, OSI-774) can be safely used up to a dose of 150 mg two times a day for 12 months” NCT00301418 ↗ “Erlotinib (tarceva) is oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).” NCT03086538 ↗ “Erlotinib (OSI-774, Tarceva) is an orally available inhibitor of human EGFR tyrosine kinase.” NCT00459901 ↗ “Phase II Study of Erlotinib (Tarceva®) in Patients With Advanced Pancreatic Adenocarcinoma” NCT00470535 ↗ “Tarceva™ (Erlotinib) Alone and of Tarceva Plus VELCADE* (Bortezomib) for Injection” NCT00283634 ↗ “This type of lung cancer may respond to a medication called erlotinib (Tarceva).” NCT00988169 ↗ “Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma” NCT00137826 ↗ “erlotinib [Tarceva], as monotherapy or intermittent dosing with docetaxel” NCT01204697 ↗ “Erlotinib (Tarceva) is a human EGFR type 1 tyrosine kinase inhibitor.” NCT00955149 ↗ “Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid” NCT02714010 ↗ “Erlotinib (Tarceva®) 150 mg po days 2-16 of each 21-day cycle.” NCT00908336 ↗ “Erlotinib (Tarceva) 150mg: Erlotinib 150mg orally each day.” NCT00153803 ↗ “EGFR+ only Tarceva® (erlotinib): 25 mg and 100 mg tablets.” NCT02233049 ↗ “Erlotinib (Tarceva™, OSI Pharmaceuticals, Uniondale, NY)” NCT00281866 ↗ “Erlotinib (Tarceva®), 150mg/day p.o during 6 months.” NCT00466089 ↗ “Tarceva™ (Erlotinib Hydrochloride) Plus Sirolimus” NCT00509431 ↗ “Erlotinib (Tarceva) and Bevacizumab (Avastin)” NCT00749567 ↗ “Tyrosine Kinase Inhibitor erlotinib (Tarceva)” NCT02321293 ↗ “capecitabine (Xeloda®)y erlotinib (Tarceva®)” NCT00873353 ↗ “Gemcitabine, Cisplatin, Erlotinib (Tarceva)” NCT00922896 ↗ “Erlotinib (Tarceva®, an EGFR Inhibitor)” NCT01205685 ↗ “Erlotinib (aka Tarceva or OSI-774)” NCT00047762 ↗ “Tarceva (Erlotinib Hydrochloride)” NCT00418327 ↗ “Erlotinib Hydrochloride (Tarceva)” NCT00903734 ↗ “Tarceva (erlotinib HCl, OSI-774)” NCT00040183 ↗ “OSI-774 (Tarceva, Erlotinib)” NCT00217529 ↗ “Tarceva (erlotinib) therapy” NCT01250119 ↗ “Drug: erlotinib [Tarceva]” NCT00940875 ↗ “Drug: erlotinib [Tarceva]” NCT01174563 ↗ “Tarceva (erlotinib HCl)” NCT00095225 ↗ “Tarceva (erlotinib HCl)” NCT00091663 ↗ “Tarceva (erlotinib HCl)” NCT00047736 ↗ “Tarceva (erlotinib HCl)” NCT00081614 ↗ “Erlotinib (Tarceva®)” NCT00547105 ↗ “Erlotinib (Tarceva®)” NCT00783471 ↗ “Erlotinib (TARCEVA®)” NCT01130779 ↗ “Erlotinib (Tarceva™)” NCT01116622 ↗ “erlotinib [Tarceva]” NCT01135498 ↗ “erlotinib [Tarceva]” NCT00556322 ↗ “erlotinib [Tarceva]” NCT01287754 ↗ “Erlotinib [Tarceva]” NCT01183858 ↗ “erlotinib [Tarceva]” NCT00718315 ↗ “erlotinib [Tarceva]” NCT00642733 ↗ “erlotinib [Tarceva]” NCT01609543 ↗ “erlotinib [Tarceva]” NCT01372384 ↗ “erlotinib (Tarceva)” NCT00903292 ↗ “erlotinib [Tarceva]” NCT00883779 ↗ “erlotinib [Tarceva]” NCT00773383 ↗ “Erlotinib (Tarceva)” NCT00585533 ↗ “Tarceva (erlotinib)” NCT00466284 ↗ “Erlotinib (Tarceva)” NCT00901901 ↗ “erlotinib [Tarceva]” NCT00531934 ↗ “Erlotinib (Tarceva)” NCT00148772 ↗ “erlotinib [Tarceva]” NCT01066884 ↗ “erlotinib [Tarceva]” NCT02013206 ↗ “erlotinib [Tarceva]” NCT01196078 ↗ “erlotinib [Tarceva]” NCT00925769 ↗ “erlotinib [Tarceva]” NCT01998919 ↗ “erlotinib (Tarceva)” NCT00598156 ↗ “Erlotinib (Tarceva)” NCT00440414 ↗ “OSI-774 (Tarceva)” NCT00137800 ↗ “Tarceva” NCT00242502 ↗ |
| Known as | Tarceva (Trademark) | “Tarceva (Trademark) (erlotinib HCl, OSI-774)” NCT00072631 ↗1“Tarceva (Trademark) (erlotinib HCl, OSI-774)” NCT00085839 ↗ |
| Known as | Tarceva(TM) (erlotinib) | “Tarceva(TM) (erlotinib)” NCT00602667 ↗ |
| Known as | TarcevaTM | “Inhibition of kinase function of EGFR by approved inhibitor Erlotinib (TarcevaTM) broadly inhibits HCV infection of all major genotypes including viral escape variants...” NCT01835938 ↗2“Erlotinib (TarcevaTM) is a newer drug which has shown benefit for patients with lung cancers that contain an EGFR mutation.” NCT00577707 ↗ “OSI-774: erlotinib, TarcevaTM” NCT00590902 ↗ |
| Known as | USAN: erlotinib hydrochloride | “USAN: erlotinib hydrochloride” NCT00054275 ↗ |
| Action | Inhibit | “selective inhibitor of EGFR tyrosine kinase activity” PMID 18591547 ↗ Jun 2008 |
| Modality | Small molecule | “Sorafenib and erlotinib are potent, orally administered receptor tyrosine kinase inhibitors with antiproliferative and antiangiogenic activities.” PMID 17699864 ↗ Aug 2007 |
| Route | Oral | “100 or 150 mg/d orally” PMID 17452677 ↗ Apr 2007 |
| Target | EGFR | “HER1/EGFR-targeted agent” PMID 17452677 ↗ Apr 2007 |